Glenmark Pharmaceuticals Limited — Updates, 05-09-2025: Press Release

Glenmark initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in resectable Stage III NSCLC. This pivotal study begins patient enrollment in India, with trials underway in Russia, Brazil, and Mexico, aiming to enhance cancer treatment accessibility.